Scleroderma-Associated Pulmonary Arterial Hypertension
A 52-year-old woman with limited cutaneous systemic sclerosis and Raynaud phenomenon presents with 8 months of progressive exertional dyspnea. She has no chest pain or syncope. Exam: JVP 10 cm, loud P2, trace lower extremity edema, sclerodactyly. ECG: RV strain. Echo: RVSP 58 mm Hg, moderate RV dilation, LVEF 60%. Right heart catheterization: RA pressure 12 mm Hg, mPAP 38 mm Hg, PCWP 12 mm Hg, cardiac output 4.0 L/min, cardiac index 2.2 L/min/m². Pulmonary function tests: FVC 78%, DLCO 38%, no restriction. V/Q scan is low probability for PE. She is on no pulmonary vasodilators.
1. Calculate the pulmonary vascular resistance and classify the pulmonary hypertension group. What does the PCWP tell you?
Read the worked answer
PVR = (mPAP − PCWP) / cardiac output = (38 − 12) / 4.0 = 6.5 Wood units.
The hemodynamics show pre-capillary pulmonary hypertension: mPAP >20 mm Hg, PCWP ≤15 mm Hg, and PVR >3 Wood units. The PCWP of 12 mm Hg argues against left heart disease (group 2 PH), which is important because the 58 mm Hg RVSP on echo could otherwise be attributed to diastolic dysfunction.
This is group 1 pulmonary arterial hypertension associated with systemic sclerosis. The low DLCO with preserved FVC also supports a pulmonary vascular process rather than interstitial lung disease. The V/Q scan being low probability makes chronic thromboembolic pulmonary hypertension unlikely, though a formal V/Q scan is still the preferred screening test for CTEPH.
The classification matters because group 1 PAH has specific vasodilator therapy, while group 2 PH is managed by treating the left heart disease.
2. Should you perform acute vasoreactivity testing? Why or why not?
Read the worked answer
No. Acute vasoreactivity testing is recommended in idiopathic PAH to identify the small subset of patients who may benefit from high-dose calcium channel blockers. It is not recommended in scleroderma-associated PAH because positive responses are rare and calcium channel blockers can cause harm, including systemic hypotension and worsening right heart failure.
In systemic sclerosis, the pulmonary vascular disease is typically fixed and proliferative. Administering a vasodilator during testing can precipitate edema or hypotension without predicting long-term benefit. Therefore, the correct next step is to start PAH-specific therapy rather than to test for vasoreactivity.
This is a common judgment point: the presence of PAH does not automatically mean vasoreactivity testing is indicated. The underlying cause determines the indication.
3. What initial PAH therapy would you choose, and how would you monitor response?
Read the worked answer
For a patient with scleroderma-associated PAH and functional limitation, initial combination therapy is preferred over monotherapy. A reasonable regimen is an endothelin receptor antagonist plus a phosphodiesterase-5 inhibitor (e.g., ambrisentan plus tadalafil). If there is more severe disease, parenteral prostacyclin therapy should be considered.
Avoid calcium channel blockers unless the patient had a documented positive vasoreactivity test, which is not the case here.
Monitoring should include:
- WHO functional class and 6-minute walk distance at baseline and follow-up.
- BNP/NT-proBNP trends.
- Echocardiography for right ventricular function and estimated pressures.
- Right heart catheterization if there is clinical worsening or before major therapy changes.
- Lung transplant referral if she is a candidate and remains symptomatic despite therapy.
Escalation should be based on objective evidence of progressive right heart failure, not on a single echo pressure.